Nadav Askari

535 total citations
10 papers, 440 citations indexed

About

Nadav Askari is a scholar working on Molecular Biology, Pharmacology and Pathology and Forensic Medicine. According to data from OpenAlex, Nadav Askari has authored 10 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 2 papers in Pharmacology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Nadav Askari's work include Protein Kinase Regulation and GTPase Signaling (5 papers), Melanoma and MAPK Pathways (5 papers) and Cancer Mechanisms and Therapy (2 papers). Nadav Askari is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (5 papers), Melanoma and MAPK Pathways (5 papers) and Cancer Mechanisms and Therapy (2 papers). Nadav Askari collaborates with scholars based in Israel, United States and France. Nadav Askari's co-authors include Oded Livnah, David Engelberg, Ron Diskin, Ricardo Capone, John C. Reed, Dayong Zhai, Ricardo G. Correa, James J. Walters, Christopher M. Shuford and Russell P. Grant and has published in prestigious journals such as Journal of Biological Chemistry, Analytical Chemistry and Biochemistry.

In The Last Decade

Nadav Askari

10 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nadav Askari Israel	9	304	79	72	47	42	10	440
Parviz Behnam‐Motlagh Sweden	13	239 0.8×	46 0.6×	101 1.4×	50 1.1×	31 0.7×	23	423
Victoria Izumi United States	13	432 1.4×	56 0.7×	137 1.9×	56 1.2×	19 0.5×	22	601
Gillian L. Dornan Canada	11	450 1.5×	80 1.0×	48 0.7×	120 2.6×	14 0.3×	15	599
Antje Dittmann Switzerland	9	295 1.0×	28 0.4×	80 1.1×	38 0.8×	16 0.4×	23	466
Hetal Brahmbhatt United States	8	417 1.4×	61 0.8×	72 1.0×	34 0.7×	28 0.7×	17	563
Sweta Iyer Australia	12	507 1.7×	80 1.0×	81 1.1×	49 1.0×	18 0.4×	17	627
Annegret Boge United States	7	376 1.2×	43 0.5×	65 0.9×	59 1.3×	15 0.4×	12	479
Daniela Brünnert Germany	13	202 0.7×	77 1.0×	56 0.8×	38 0.8×	16 0.4×	25	373
Alexey V. Zamaraev Russia	9	286 0.9×	57 0.7×	69 1.0×	32 0.7×	13 0.3×	27	389
Jørn Skavland Norway	14	233 0.8×	143 1.8×	86 1.2×	15 0.3×	19 0.5×	26	478

Countries citing papers authored by Nadav Askari

Since Specialization

Citations

This map shows the geographic impact of Nadav Askari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadav Askari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadav Askari more than expected).

Fields of papers citing papers by Nadav Askari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadav Askari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadav Askari. The network helps show where Nadav Askari may publish in the future.

Co-authorship network of co-authors of Nadav Askari

This figure shows the co-authorship network connecting the top 25 collaborators of Nadav Askari. A scholar is included among the top collaborators of Nadav Askari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadav Askari. Nadav Askari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Natan, Sari, et al.. (2022). Genetika+: Precision Medicine Solutions for Mental Health. Pharmacogenomics. 23(10). 571–574. 1 indexed citations

2.

Shuford, Christopher M., et al.. (2017). Absolute Protein Quantification by Mass Spectrometry: Not as Simple as Advertised. Analytical Chemistry. 89(14). 7406–7415. 68 indexed citations

3.

Askari, Nadav, Ricardo G. Correa, Dayong Zhai, & John C. Reed. (2011). Expression, purification, and characterization of recombinant NOD1 (NLRC1): A NLR family member. Journal of Biotechnology. 157(1). 75–81. 28 indexed citations

4.

Correa, Ricardo G., Nadav Askari, Dayong Zhai, et al.. (2011). Discovery and Characterization of 2-Aminobenzimidazole Derivatives as Selective NOD1 Inhibitors. Chemistry & Biology. 18(7). 825–832. 50 indexed citations

5.

Paillas, Salomé, Florence Boissière‐Michot, Frédéric Bibeau, et al.. (2010). Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma. Cancer Research. 71(3). 1041–1049. 76 indexed citations

6.

Askari, Nadav, Jonah Beenstock, Oded Livnah, & David Engelberg. (2009). p38α Is Active in Vitro and in Vivo When Monophosphorylated at Threonine 180. Biochemistry. 48(11). 2497–2504. 36 indexed citations

7.

Diskin, Ron, et al.. (2007). Intrinsically active variants of all human p38 isoforms. FEBS Journal. 274(4). 963–975. 56 indexed citations

8.

Askari, Nadav, et al.. (2006). MAP-quest: Could we produce constitutively active variants of MAP kinases?. Molecular and Cellular Endocrinology. 252(1-2). 231–240. 18 indexed citations

9.

Askari, Nadav, et al.. (2006). Hyperactive Variants of p38α Induce, whereas Hyperactive Variants of p38γ Suppress, Activating Protein 1-mediated Transcription. Journal of Biological Chemistry. 282(1). 91–99. 42 indexed citations

10.

Diskin, Ron, Nadav Askari, Ricardo Capone, David Engelberg, & Oded Livnah. (2004). Active Mutants of the Human p38α Mitogen-activated Protein Kinase. Journal of Biological Chemistry. 279(45). 47040–47049. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact